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Abstract
Cancer poses danger because of its unregulated growth, development of resistant subclones, and metastatic
spread to vital organs. Although the major transitions in cancer development are increasingly well un-
derstood, we lack quantitative theory for how chemoprevention is predicted to affect survival. We employ
master equations and probability generating functions, the latter well known in statistical physics, to
derive the dynamics of tumor growth as a mean-field approximation. We also study numerically the as-
sociated stochastic birth-death process. Our findings predict exponential tumor growth when a cancer is
in its early stages of development and hyper-exponential growth thereafter. Numerical simulations are in
general agreement with our analytical approach. We evaluate how constant, low impact treatments affect
both neoplastic growth and the frequency of chemoresistant clones. We show that therapeutic outcomes
are highly predictable for treatments starting either sufficiently early or late in terms of initial tumor size
and the initial number of chemoresistant cells, whereas stochastic dynamics dominate therapies starting
at intermediate neoplasm sizes, with high outcome sensitivity both in terms of tumor control and the
emergence of resistant subclones. The outcome of chemoprevention can be understood in terms of both
minimal physiological impacts resulting in long-term control and either preventing or slowing the emer-
gence of resistant subclones. We argue that our model and results can also be applied to the management
of early, clinically detected cancers after tumor excision.
Author summary
One of the principal risks of aggressive chemotherapy is the selection of cells that are at the origin
of relapse and are refractory to subsequent treatments. Alternative approaches based on management
models usually target clinically detected tumours or residual cancers. These therapies carry the risk of
not being able to control fast growing subclones or resistant lineages. We develop a mean-field approach
to evaluate low impact chemoprevention. Effective management slows or prevents evolution though the
incorporation of fitness-enhancing driver mutations, and the emergence of chemoresistance. Dynamics
are highly predictable for sufficiently small or large initial tumour sizes, and increasingly stochastic for
intermediate-sized tumours. Based on empirical parameter estimates, we predict that the optimal daily
levels of reduction in tumour growth for sufficiently small neoplasms are between 0.1% and 0.2%. This
corresponds to reducing the net growth rate of the existing tumour to below zero (0.1% growth reduction),
but not so much so as to select for subsequent driver mutations (0.2% growth reduction). Satisficing based
on chemoprevention offers an alternative approach for people at high risks of life-threatening cancers.
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21 Introduction
Mathematical models play an important role in describing and analyzing the complex process of carcino-
genesis. Natural selection for increases in tumor cell population growth rate can be represented as the
net effect of increased fission rates and/or decreased apoptosis (e.g., [1]). Relatively rare driver mutations
confer such a net growth advantage, whereas numerically dominant passenger mutations with initially
neutral or mildly deleterious effects [2–4] can only initially grow in frequency due to genetic hitchhiking.
Amongst the many passengers in a growing tumor, some can contribute to cell chemoresistance, and a
sufficiently large tumor will contain different clones that, taken as a group, can resist most, if not all,
possible chemotherapies (see [5] for resistance to imatinib). Chemotherapeutic remission followed by re-
lapse suggests that these resistant cells are often at low frequencies prior to therapy, either due to genetic
drift or costs associated with resistance. Resistant phenotypes subsequently increase in frequency during
chemotherapy, and through competitive release, they may incorporate one or more additional drivers,
resulting in accelerated growth compared to the original tumor [6].
Previous mathematical studies have considered alternatives to attempting to minimize or eradicate
clinically diagnosed cancers with maximum tolerated doses (MTD) of chemotherapeutic drugs. This
body of work indicates that MTD is particularly prone to select for chemoresistance (e.g., [7–9]), and
empirical studies support this basic prediction [10]. Numerous alternatives to the goal of cancer mini-
mization/eradication have been investigated (e.g., [7, 11–14]). For example, Komarova and Wodarz [11]
considered how the use of one or multiple drugs could prevent the emergence or curb the growth of
chemoresistance. They showed that the evolutionary rate and associated emergence of a diversity of
chemoresistant lineages is a major determinant in the success or failure of multiple drugs versus a single
one. Foo and Michor [7] evaluated how different dosing schedules of a single drug could be used to slow
the emergence of resistance given toxicity constraints. One of their main conclusions is that drugs slowing
the generation of chemoresistant mutants and subsequent evolution are more likely to be successful than
those only increasing cell death rates.
These and other computational approaches have yet to consider the use of chemoprevention to reduce
cancer-associated morbidity and mortality. Prevention, more generally, encompasses life-style changes,
interventions or therapies in the absence of detectable invasive carcinoma (e.g., [15–18]). In depth con-
sideration of preventive measures and their likely impact on individual risk and epidemiological trends is
important given the virtual certitude that all people have pre-cancerous lesions, some of which may trans-
form into invasive carcinoma [19,20], and concerns as to whether technological advances will continue to
make significant headway in treating clinically detected cancers [21,22].
Here we model how chemoprevention affects tumor progression and the emergence of chemoresistant
lineages. Previous study has considered the effects of deterministic and stochastic processes on tumor
growth and the acquisition of chemoresistance [2, 11, 23]. We consider both processes through exact
solutions and numerical simulations of master equations, using the mean field approach. A mean field
approach assumes a large initial number of cells [24] and averages any effects of stochasticity, so that
an intermediate state of the system is described by a set of ordinary differential equations (i.e., master
equations; [25]). Solutions to these are complex even in the absence of the explicit consideration of both
drivers and passengers [26]. Our approach [27, 28] follows the dynamics of the relative frequencies of
subclones, composed of identical cells, instead of the fate of individual cells. We derive the dynamics for
the expected total number of cells within a tumor at any given time.
We show that the expected mean tumor size can be substantially different from the median, since the
former is highly influenced by outliers due to tumors of extremely large size. We then consider constant
chemopreventive treatments, starting at a given tumor size and number of chemoresistant mutations. We
find that treatment outcome can be highly sensitive to initial conditions. Not surprisingly, initially small
tumors are more likely to be controlled than larger tumors employing low dose therapies, whereas large
tumors follow deterministic growth and are both difficult to control in overall size and in the emergence
of resistance. In contrast, there is a range of intermediate size tumors, where stochastic dynamics become
3significant, and clinical outcome is highly sensitive to the commencement time (i.e., initial tumor size) of
treatment regimes.
2 Results
Parameter Variable Value Reference
Time step (cell cycle length) T 4 days [2]
Selective advantage s 0.4% [2]
Cost of resistance c 0.1%
Mutation rate to acquire an additional driver u 3.4× 10−5 [2]
Mutation rate to acquire resistance v 10−6 [11]
Maximal number of additional drivers N 5
Initial cell population n(0) 106
Pre-resistance level κ 0.01% [29]
Number of replicate numerical simulations - 106
(excl. the ones with extinction)
Table 1. Canonical parameter values used in this study.
We study a low intensity, constant treatment regime that starts at time t = 0. First, we study mean-
field dynamics by considering the distribution Ht(x) of tumor sizes x at time moments t, and examine
effects on the mean n(t) = 〈Ht(x)〉.
Using the master equations, we derive an analytical expression for the dynamics n(t). Namely, we
use (8)-(9) and (13)-(14) (see Methods section) to obtain the dynamics of the expected tumor size
n(t) = n(0)
(
(1− κ)
(
1 +
v
2
e(σ−c)t − 1
σ − c
)
+ κe(σ−c)t
)
exp
[
(s− σ)t+N ln
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2N
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s
)]
, (1)
and the frequency of resistant cells within a tumor
nres(t)
n(t)
=
(1− κ) v2 e
(σ−c)t−1
σ−c + κe
(σ−c)t
(1− κ)(1 + v2 e
(σ−c)t−1
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Here, time t is normalized so that any event occurs at rate equal to unity, or t = τ/T . In the following,
we use the variable t as shorthand for t = τ/T .
Fig. 1 (A and a) shows the excellent correspondence between numerical experiments and analytical
results for σ on the order of s.
Equation (1) is simplified for two limiting cases. In the early stages of tumor growth, the value n(t)
changes according to a hyper-exponential law:
n(t) ≈ n(0)
(
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)
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[
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2
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s
]
.
while at later stages the most aggressive subclone persists, being sensitive if σ < c (n(t) ∝ es(N+1)t) and
resistant otherwise (n(t) ∝ es(N+1)t−c).
A more detailed study of the distribution Ht(x) reveals that the mean n(t) diverges importantly from
median behavior in the majority of cases, since the former is strongly influenced by outliers. Fig. 1(B)
and Suppl. Fig. S1 illustrate examples where the mean trajectory deviates from the median, and exceeds
the 95% confidence interval at approximately 22 years into the simulation.
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Figure 1. Mean field dynamics concord with numerical simulations. (A) Effect of treatment
level and observation time on mean tumor size. (Inset) Mean frequency of resistant cells within tumors
corresponding to three of the cases in A. Lines are analytically computed mean-field trajectories, while
dots are numerical simulations (see Methods section for details). (B) Dynamics of mean and median
tumor size, and percentiles around the mean (shaded areas), assuming a fixed constant treatment of
0.6%. Treatments start at t = 0, the maximal number of additionally accumulated drivers is 3. See
Table 1 for other parameter values.
To see how alternative formulations affect the results, we investigate Hx(t), which is the distribution
of times t when a tumor reaches a given threshold size x. We assume x = M = 109 cells (i.e., the lower
boundary for clinical detection of a tumor - approximately 1cm3 in volume). Note that the results below
can be generalized for other values of M .
Based on extensive numerical experiments, we find that the means of the distributions 〈Ht(x)〉 and
〈Hx(t)〉 (as well as other characteristics such as the mode and the median) are the same only in case
of no treatment (σ = 0). The reason for these apparent discrepancies is that a tumor has two distinct
subpopulations (sensitive and resistant), meaning that the distributions Ht(x) and Hx(t) are bimodal.
Trivially, this does not occur for σ = 0, since the resistant part is negligible (at a mutation-selection
balance).
We perform three sets of numerical experiments to study how variation in any one of the following
parameters–the selective advantage s, the cost of resistance c, or the initial number of cells n(0)–influences
the properties of the distribution HM (t).
Variation in the selective advantage s, with c = 0.1% and n(0) = 106 cells being fixed, leads to Fig. 2.
We see that tumor growth is mainly driven by its non-resistant part for relatively low impact treatments
σ < 2s. The tumor changes from being mainly non-resistant to resistant at σ ≈ 2s, which is reflected by
the emergence of an inflection point in the trajectory of the median (indicated by C in Fig. 2). Notice that
the detection times are also most variable at σ ≈ 2s. The median changes smoothly at high treatment
levels (σ > 2s), tending to a horizontal asymptote. This is explained by the fact that the sensitive part
is heavily suppressed at high treatment levels, meaning that the dynamics are strongly influenced by an
actual time point when the resistance mutation occurs.
5The inflection point at σ ≈ 2s is due to the accumulation of additional drivers within tumors and
associated increases the likelihood that the tumor eventually resists treatment if no resistant cells were
initially present. Since the initial population consists of 106 cells, in the absence of treatment, a new cell
with one additional driver and associated fitness (2s−σ) will appear very rapidly. Such a tumor can only
be suppressed only if we apply the treatment with σ > 2s. This is supported by additional numerical
experiments, where we vary the maximal number of allowed driver mutations N , see Fig. 4(A). We see
that the inflection point σ ≈ 2s disappears when N = 0. Similarly, we may expect inflection points
around σ = 3s, 4s and so on, which is shown in Suppl. Fig. S2 or in Suppl. Video S3 and where the
resistant mutation is knocked out. In contrast, when the resistant mutation is present, an appearance of
many inflection points is blurred by higher growth of the resistant part of a tumor: only two humps are
noticed in Fig. 2 for the largest value of cost of resistance c = 0.4% and one hump for smaller values of c.
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Figure 2. Treatment level affects both detection time and frequency of resistance. (A) The
median and 95% confidence intervals (shaded or hatched areas) of detection times for 0.4% and 0.8%
selective advantages (see legend). (B, C and D) Three samples of the distribution of detection times for
corresponding points B, C and D, shown in A. Dashed black line is the mean and the dotted line is the
median. Bottom panel shows the mean number of additionally accumulated drivers within tumors over
periods of 3 months. Light red points correspond to tumors with a majority of resistant cells; light blue
points are for tumors with a majority of non-resistant cells. Color-code indicates the level of resistance
in detected tumors over 3 month intervals. No pre-resistance is assumed. Other parameter values are as
in Table 1. Note that the detection time in A is log-transformed.
Counterintuitively, if the cost of resistance is low to moderate then early-detected tumors are more
likely to be resistant under constant treatments than those detected at later times (B, C and D in
Fig. 2). While a resistance mutation emerges, the tumor grows faster under selection (despite the very
low impact of therapy on sensitive cancer cells) and is therefore more likely to be detected at earlier times.
By the time of detection, non-resistant tumors usually accumulate up to 4 additional drivers on average,
while resistant tumors have fewer. For larger values of c, an additional non-regularity emerges (segment
BCD in Fig. 3), appearing at σ ≈ 3s and is associated with tumors having a majority of cells with 3
total drivers. This region is also characterized by a different transition to complete resistance (compare
Suppl. Video S1 and S2 for relatively low and high costs of resistance, respectively). For example, at
point B tumors with a majority of non-resistance have less variable detection times than tumors with a
majority of resistant cells (A and corresponding panel B in Fig. 3). Treatment levels along the segment
BCD result in tumors that are more likely to be resistant as one goes from the center to the tails of the
6Treatment intensity, %
D
et
ec
tio
n 
ye
a
r
20
40
60
80
100
0.0 0.4 0.8 1.2 1.6
l
l
l
l
l l l l l
l
l
l l l l
lB
C D
Cost resist, %
0.1
0.4
A
Fr
eq
ue
nc
y
20 50 80 110
0
0.
01
5
0.
03 B
M
ea
n 
# 
of
 d
riv
e
rs
1
2
3
4
5
l
l
l
l
l
l
ll
l
l
l
ll
llllllllllll
lll
lllllllllllllllllllllllllllllllllllll
lllll
llllllll
l
l
ll
20 50 80 110
Detection year
C
lll
l
l
l
ll
l
ll
llllllllllll
lllll
lllllll
llllllllllllllllllllllllllllllllllll
lll
llll
l
l
ll
20 50 80 110
D
ll
ll
l
ll
lll
lllllllllllllllllllllllllllllllllllllllllllll
l
lllll
lll
llllll
ll
l
l
0%
50%
100%
Resistance
Figure 3. Higher costs of resistance lead to slower, but more variable growth. The median
and 95% confidence intervals for detection times when the cost of resistance is varied. The selective
advantage is fixed at 0.4%. Other conditions as for Fig. 2.
distribution HM (t). This differs qualitatively from the previous case of low cost of resistance, where the
tumors are less resistant in a tail of the distribution.
The initial cell number n(0) affects both the median and distribution of detection times Fig. 4(B). For
large initial tumors, growth is deterministic and exponential. As the initial size is decreased (n(0) = 106
to 105), stochastic effects are increasingly manifested by the appearance of an inflection point in the
trajectory of the median, as well as increased variability in detection times.
Whereas M = 109 cells are an approximate clinical detection threshold for many solid tumors, ap-
proximately M¯ = 1011 cells could be attained for certain otherwise undetectable cancers, and are only
discovered in late stage, metastatic disease [30]. Using numerical experiments, we find that the difference
in times when a tumor reaches M and M¯ respectively, is 4.7± 0.2 years (mean±s.d.).
A tumor is likely to be eradicated under a range of constant treatments if it has n(0) = 105 or fewer
initial cells; a tumor is virtually certain to persist for n(0) = 107 cells or greater, as it is shown in
Suppl. Fig. S3. In other words, our model indicates that tumors that are c. 1% of clinically detectable
size will typically be impossible to eradicate.
The above analysis assumes zero initial resistance within a tumor. Given mutation rates assumed here
we can expect that many tumors with one million cells will already contain resistant cells. We extend our
study to other values of initial resistance level, denoted by κ. As shown in Fig. 4(C) larger values of κ
create a transition from stochastic to deterministic tumor growth. As expected, larger κ results in worse
control outcomes, with a threshold for treatment failure - tumors can only be eradicated for σ > 2s (see
the inset Fig. 4(C)).
Finally, we briefly consider how competition affects the results presented above. We assume for
simplicity that sensitive cells inhibit the growth of resistant cells (i.e., chemoresistance has both a constant
cost and an additional cost in proportion to sensitive cell number). Such assumption in its simple form
leads to more variability in tumor growth and, as expected, delays in cancer detection Fig. 4(D) and
a positive correlation with treatment success, see the inset Fig. 4(D), which can be understood as the
proportion of numerical experiments in which the tumor stays undetected.
710
20
40
60
80
100
0.0 0.4 0.8 1.2 1.6
D
et
ec
tio
n 
ye
a
r
A
l
l
l
l l l l l l l l l l l l
l
l
l
l
l
l
l l l l l l l l l
Max add.drvs
0
5
0
50
100
0.0 0.8 1.6
Tr
e
a
tm
en
t f
a
ilu
re
,
 
%
0 0.4 0.8 1.2 1.6
l
l
l
l
l
l
l
l l l l l l l l
l
l
l
l
l
l
l l l l l l l l l
l
l
l
l
l
l
l l l l l l
l l l
Init popul n(0)
105
106
107
B
0
50
100
0.0 0.8 1.6
10
20
40
60
80
100
0.0 0.4 0.8 1.2 1.6
Treatment intensity, %
D
et
ec
tio
n 
ye
a
r
C
l
l
l
l
l
l
l l l l l l l l ll l l l l l l l l
l
l l l l l l l l l
Pre−resist., %
0
0.01
0.02
0
50
100
0.0 0.8 1.6
Tr
e
a
tm
en
t f
a
ilu
re
,
 
%
0.0 0.4 0.8 1.2 1.6
Treatment intensity, %
D
l
l
l
l
l
l
l l l l l l l l l
l
l l
l l l l l l l
l l l
l l l l l
Compet. param.
0
10−5
0.01
0
50
100
0.0 0.8 1.6
Figure 4. Sensitivity analysis of several key parameters. The median (think line) and 95%
confidence intervals (shaded areas with dashed boundaries) for the distribution of detection times.
Parameter values are as in Table 1, except the one being varied: (A) maximal number of additionally
accumulated drivers; (B) initial cell number n(0); (C) level of initial partial resistance of a tumor; (D)
competitive parameter value α. The competition is implemented by introducing an exponential factor
in the fitness calculation: fi0 = s(i+ 1)− σ and fi1 = s(i+ 1)e−αS − c, where S =
∑
i ni0 is the number
of non-resistant cells and α characterizes the strength of competition. The insets show failure with
respect to the change in the treatment level. The color-code for points indicates the average level of
resistance within tumors, analogous to Fig. 2. The insets show the percentage of cases in simulations,
leading to detection of a tumor rather than its extinction or keeping its size below the detection
threshold. For simplicity of representation, only the median is indicated in B, C and D for the baseline
case, which is shown in green in A and with all parameter values, indicated in Table 1.
83 Discussion
Maximum tolerated dose chemotherapies present numerous challenges, ostensibly the major one being
the selection of resistant phenotypes, which are possible precursors for relapse [31]. Over the past decade,
several alternative approaches have been proposed, where the objective is to manage rather than eradicate
tumors (e.g., [8, 11, 13, 14, 32, 33]. Tumor management attempts to limit cancer growth, metastasis, and
reduce the probability of obtaining resistance mutations through micro-environmental modification or
through competition with non-resistant cancer cell populations or with healthy cells. These approaches
usually involve clinically diagnosed cancers: either inoperable tumors or residual cancers after tumor
excision. In the former situation tumors are typically large enough in size to contain numerous resistance
mutations. In many, if not most, cases these neoplasms will have metastasized, meaning greater variability
both in terms of phenotypes and hence potential resistance to chemotherapies, and in penetrance of
therapeutic molecules to targeted tumor cells [34, 35]. The latter situation involves smaller, residual
cancer cell populations, but composed of high frequencies of resistant variants or dormant cells [34].
Both scenarios are likely to involve cancer cell populations with large numbers of accumulated driver
mutations, which ostensibly contribute to the speed of relapse. Thus, management of clinically detected
tumors need not only limit the proliferation and spread of refractory subpopulations (Fig. 2-4), but should
also aim to control the growth of multi-driver clones (Suppl. Fig. S2).
We mathematically investigated an alternative strategy, chemoprevention through satisficing, where a
satisfactory objective is defined from the outset for patients at a high risk of contracting a life-threatening
cancer. Such objectives can be complex, involving minimal side effects, defining acceptable risks of
developing a lethal cancer at a later time, and realistic maximum expected frequencies of chemoresistant
lineages. Neoplasms in our model system could correspond to pre-cancerous states of dyplasia, carcinoma
in situ, or to invasive carcinoma, but the relative frequency of these different stages for tumors of the initial
sizes modeled here are unknown; nor is it known how chemopreventive therapies affect cell populations
in these different states. Several authors have previously argued for how constant or intermittent low
toxicity therapies either before or after tumor discovery could be an alternative to maximum tolerated dose
chemotherapies [18,36], but to our knowledge no study has actually quantified the modalities (treatment
start time, dose) for such approaches using empirically derived parameter estimates [2, 12,37].
Our model indicates that daily reductions in population growth of s < σ < 2s, corresponding to
0.1%-0.2%, is sufficient in most cases to control neoplasm expansion for tumors less than about 1 million
cells, and harboring no resistance mutations and only one driver mutation at the start of therapy. We find
that such nascent tumors can be managed for tens of years without growing to life-threatening levels, and
that the duration of successful prevention is sensitive to both initial tumor size and treatment intensity.
Specifically, tumors growing beyond approximately the reciprocal of the driver mutation rate (c 106 cells)
are exponentially increasingly likely to produce a faster growing subclone with a new driver. Such a
subclone is even more likely, once it reaches ∼1/u cells, to produce a new subclone with an additional
driver, and so on. The result over sufficiently long periods is a hyper-exponential increase in tumor size.
Given that mutation rates for chemoresistance are thought to be on the order of 10−6 per cell division [11],
this means that tumor size is also a sensitive predictor of the likelihood of chemoresistance, and thus the
potential for chemopreventive management to slow the progression of a potentially lethal cancer.
Indeed, one of our central results is the sensitivity of tumor growth to size at the commencement of
therapy (Fig. 4(C)). Deterministic equations provide an accurate description of such growth for sufficiently
small (. 105) or large (>106) initial tumor sizes. We found that sufficiently small tumors were controlled
and sometimes eradicated if therapeutic reductions in population growth exceeded 2s. Larger tumors,
though affected by therapy, were impossible to control or to eradicate, because of the presence of resistance
mutations. This effect was mitigated to some extent by cell-cell competition (Fig. 4(D)), but the process
of competition as modeled here was not sufficient to permit tumor control (but see [33]). Moreover,
we found that tumors approximately between 105 and 106 cells had more variable, stochastic outcomes,
meaning that a given preventive therapeutic regimen may or may not be successful due to the chance
9emergence of driver mutations and local extinctions. This result emphasizes not only the sensitivity of
tumor control to initial size (i.e., time at which therapy commences), but also the accurate assessment
of changes in cancer risk for different therapeutic alternatives. Although not investigated in the context
of cancer therapies, the results of Bozic and colleagues [2] indicate that achieving a tumor size where
driver mutations become probable, distinguishes patients harboring small tumors after 25 years from
those developing life-threatening tumors over this same period (see Fig. 1 in [2]). In their simulations
like ours, the time to emergence of the second driver mutation is a good predictor of future tumor growth.
Our theory also highlights two potentially contrasting objectives of cancer prevention: managing
tumor size vs managing resistance mutations. We show the sensitivity of these two outcomes to treatment
levels, especially near the threshold 2s. Treatments at or beyond 2s effectively offset or reduce sensitive
cell growth, leaving a large subpopulation of resistant cells that are released from competition and can
rapidly obtain additional driver mutations. Treatments just below 2s also reduce tumor growth, but
maintain high frequencies of sensitive cells, which potentially compete with resistance cells, thereby
reducing overall resistance cell numbers. Adopting the latter strategy could make a difference to long-
term outcomes, especially in cases where the constant therapy is discontinued, or ulterior attempts are
made at high dose chemotherapy.
Some empirical studies support the role of certain molecules in chemoprevention [17]. For example,
Silva and colleagues [38] parameterized computational models to show how low doses of verapamil and
2-deoxyglucose could be administered adaptively to promote longer tumor progression times. These drugs
are thought to increase the costs of resistance and the competitive impacts of sensitive on resistant cancer
cell subpopulations. However, some of the most promising results have come from studies employing non-
steroidal anti-inflammatory drugs (NSAIDs), including experiments [39], investigations of their molecular
effects [40,41], and their use [42]. For example, Ibrahim and coworkers [39] studied the action of NSAIDs
and specifically sodium bicarbonate in reducing prostate tumors in male TRAMP mice (i.e. an animal
model of transgenic adenocarcinoma of the mouse prostate). They showed that mice commencing the
treatment at 4 weeks of age had significantly smaller tumor masses, and that more survived to the end
of the experiment than either the controls or those mice commencing the treatment at an older age.
Kostadinov and colleagues [40] showed how NSAID use in a sample of people with Barrett’s esophagus
is associated with reductions in somatic genomic abnormalities and their growth to detectable levels. It
is noteworthy that it is not known to what extent reductions in cancer progression under NSAIDs is
due to either cytotoxic or cytostatic effects, or both. Although we do not explicitly model cytotoxic or
cytostatic impacts, therapies curbing net growth rates, but maintaining them at or above zero, could
be interpreted as resulting from the action of either cytotoxic and/or cytostatic processes. In contrast,
therapies reducing net growth rates below zero necessarily have a cytostatic component. Our model, or
modifications of it to explicitly include cytotoxic and cytostatic effects, could be used in future research
to make predictions about optimal dose and start times to achieve acceptable levels of tumor control,
or the probability of a given tumor size by a given age. Lorz and coworkers [9] recently modeled the
employment of cytotoxic and cytostatic therapies alone or in combination and showed how combination
strategies could be designed to be superior in terms of tumor eradication and managing resistance than
either agent used alone.
Decisions whether or not to employ chemopreventive therapies carry with them the risk of a poorer
outcome than would have been the case had another available strategy, or no treatment at all, been
adopted [43]. This issue is relevant to all preventive approaches, where alterations in life-style, removal
or treatment of pre-cancerous lesions, or medications may result in unwanted side effects or potentially
induce new invasive neoplasms (e.g., [44]). Chemopreventive management prior to clinical detection
would be most appropriate for individuals with genetic predispositions, familial histories, elevated levels
of specific biomarkers, or risk-associated behaviors or life-styles [16–18,45,46]. Importantly, our approach
presupposes that the danger a nascent, growing tumor presents is proportional to its size and (implicitly,
all else being equal) a persons age. Due caution is necessary in applying our results, since studies have
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argued that metastatic potential rather than tumor size may be a better predictor of future survival
[47–49].
We have modeled preventive approaches to managing risks of future lethal cancers. However, our
model also could be applied to scenarios where an invasive carcinoma is discovered early in progression.
In such cases, tumor clones are likely to harbor greater numbers of driver mutations and show higher
levels of genomic instability and standing genetic heterogeneity than the earlier stages targeted by chemo-
prevention. Higher aptitude for growth and mutation (adaptation) in clinical tumors could mean that
outcomes are less sensitive to cancer cell numbers as we found in the prevention scenario. We suggest that
the frequency distribution of driver mutations and the distribution of resistant subclones within these
lineages could instruct decisions of the time course of treatment levels, with the aims of satisfactory tumor
growth, metastasis, and resistance control. Although residual cancer cell populations from excised tumors
and associated micro-metastases are often difficult to assess with accuracy [50], our results suggest that
if order of magnitude estimates are possible, than low dose, constant approaches could be optimized, and
according to our model, will always be superior to aggressive chemotherapies even if resistance mutations
are likely to be present.
4 Models and methods
4.1 Conceptual framework
Let each cell in a population be described by two characteristics. The first is its resistance status, which
is either “not resistant” (j = 0) or “resistant” (j = 1). The probability of a resistant mutant emerging
during cell division is assumed constant (v). The second property is the number of accumulated driver
mutations in a given cell line (maximum N). The mutation rate at any locus resulting in the addition of
a driver is u, and we assume no back mutation. Thus, the genome of a cell in our model is composed of
N potential driver loci and one chemoresistance locus.
We initially assume that at each time step cells either divide or die, but do not compete for space or
limiting resources. The fitness function fij is the difference between the birth and death rates of a cell
and is defined by the number of accumulated drivers (i = 0, 1, . . . , N) and resistance status (j = 0, 1).
A chemosensitive cancerous cell with a single driver has selective advantage s. Any additional drivers
add s to fitness, while resistance is associated with a constant cost c. Exposure to a single chemotherapy
treatment affects only non-resistant cells (j = 0), incurring a loss σ ∈ [0, 1] to their fitness. We assume
that all parameters c, s and σ are arbitrarily small ( 1).
Fitness is
fij = s(i+ 1)− σ(1− j)− cj . (3)
The assumption of driver additivity is a special case of multiplicative fitness, and both are approximately
equivalent for very small s.
4.2 Numerical simulations
To simulate tumor growth, we adopt a discrete time branching process for the cell-division process [2,51],
which is usually referred to as a discrete time Galton-Watson process [52]. For each numerical experiment
we initiate a tumor of a given size with cells of a type i = 0, and proportion of resistant cells within a
tumor κ (0 ≤ κ ≤ 1). Table 1 presents baseline parameter values employed in this study.
At the beginning of each time step, the number of cells is nij(t). The number of cells at next step (t+1)
is then sampled by a multinomial distribution. If we let Bij be the number of births in the population,
Dij the number of deaths, M
(u)
ij and M
(v)
ij the number of mutations from class (i, j) to classes (i+ 1, j)
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and (i, j + 1) respectively, then the multinomial distribution is
P [(Bij , Dij ,M
(u)
ij ,M
(v)
ij ) = (k1, k2, k3, k4)] =
nij(t)!
k1!k2!k3!k4!
(bij(1− ui − vj))k1dk2ij (bijui)k3(bijvj)k4 ,
where ui = u(1− i/N) and vj = v(1− j) (i = 0, . . . , N , j = 0, 1).
The number of cells of type (i, j) at time step t+ 1 is now given by
nij(t+ 1) = nij(t) +Bij −Dij +M (u)i−1,j +M (v)i,j−1 ,
where we assume M
(u)
−1,j = 0 and M
(v)
i,−1 = 0.
We conducted numerical experiments of the above model, each with the same initial states, but each
using a unique set of randomly generated numbers of a branching process.
4.3 Code
All calculations were made using programs, written in C, and the free, open-source statistical package
R [53]. The color palette for figures was adopted from [54]. Code for all calculations, and for producing
all of the figures, is available at [55] and can be used freely for non-commercial purposes.
4.4 Mean-field dynamics
We use the mean-field approach, see e.g. [24], which approximates the behavior of a system consisting of
many cells, so that the effects of stochasticity are averaged and an intermediate state is described by a
set of ordinary differential equations.
Master equations We write master equations to track the probability Pij(t) that a randomly chosen
cell from the population of tumor cells will be of type (i, j) at time t.
The temporal dynamics of probabilities Pij(t), i = 0, 1, . . . , N , where N is the maximal number of
additionally acquired drivers and j = 0, 1, are described by
dPij(t)
dt
= Pij + uP(u)ij + vP
(v)
ij .
Here, the right-hand side is a superposition of probabilistic in- and out-flows from different mutational
states to the current one (i, j). The function Pij describes the growth of subclone (i, j) and is proportional
to the probability Pij(t), multiplied by the difference between fij and the average fitness over the whole
population f¯ =
∑
i,j fijPij(t). P
(u)
ij and P
(v)
ij represent the probabilistic flows of mutations. For P
(u)
ij , a
driver is added from class (i− 1, j) to (i, j) in proportion to the probability Pi−1,j(t), the probability of
cell birth bi−1,j , and the probability of a zero locus being chosen from N total loci consisting of N−(i−1)
other zero loci. A similar approach is used to define the outflow term for the probability from class (i, j)
to (i+ 1, j). The second term P(v)ij is the probability of mutating to therapeutic resistance ((i, j = 0) to
(i, j = 1)), and is proportional to Pi0(t) and birth rate bi0. Finally, all terms are summed, taking into
account the initial conditions: P00(0) = 1− κ, P01(0) = κ and Pij(0) = 0 for any other i or j.
The above elements lead to the following system of ordinary differential equations (ODEs):
dPij(t)
dt
= (fij − f¯)Pij(t) + u
[(
1− i− 1
N
)1 + fi−1,j
2
Pi−1,j(t)−
(
1− i
N
)1 + fij
2
Pij(t)
]
−
v(1− 2j)1 + fi0
2
Pi0(t) ,
(4)
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where some probabilities Pij could, theoretically, take on negative values, e.g. P−1,j(t), when i = 0, in
which case, they are set to zero.
A simple transformation
pij(0) = Pij(0), pij(t) = Pij(t) exp
(∫ t
0
f¯(r) dr
)
,
allows omitting the term f¯ from equation (4) and to linearize the latter with respect to the new “trans-
formed” probabilities pij(t). This gives
dpij(t)
dt
= fijpij(t) + u
[(
1− i− 1
N
)1 + fi−1,j
2
pi−1,j(t)−
(
1− i
N
)1 + fij
2
pij(t)
]
+
v
1 + fij
2
(jpi,j−1(t) + (j − 1)pij(t)) ,
(5)
where, for convenience, we write (jpi,j−1(t) + (j − 1)pij(t)) instead of (1− 2j)pi0(t).
Probability generating function approach With the master equations (5), we apply the probability
generating function (p.g.f.) method [25, 56] to transform the system of (2N + 1) ordinary differential
equations to a Hamilton-Jacobi (HJ) equation, that is, a first order partial differential equation.
We define the p.g.f. as the polynomial over all modified probabilities pij of the form
G(ξ, η, t) =
N∑
i=0
1∑
j=0
ξiηjpij(t) , (6)
where ξ and η are variables that can be viewed as the momentum of an auxiliary Hamiltonian system
governing the leading-order stochastic dynamics of the system [57]. Notice that the function G(ξ, η, t) is
linear with respect to η.
Suppose that the function G(ξ, η, t) is defined, one can then obtain all characteristics of the stochastic
process such as the average tumor size n(t) and the average frequency nres(t)/n(t) of resistant cells within
a tumor. The former quantity is
dn(t)
dt
= n(t)f¯(t) .
Using the normalization condition for the probability:
∑
i,j Pij(t) = 1, we obtain
G(ξ = 1, η = 1, t) = exp
(∫ t
0
f¯(r) dr
)
,
and then
n(t) = n(0) exp
(∫ t
0
f¯(r) dr
)
= n(0)G(ξ = 1, η = 1, t) , (7)
where the initial tumor size n(0) is sufficiently large. The latter quantity is written as follows
nres(t)
n(t)
=
N∑
i=0
Pi1(t) =
N∑
i=0
pi1(t) exp
(−∫ t
0
f¯(r) dr
)
=
∂G/∂η
G(ξ, η, t)
∣∣∣
ξ=1,η=1
. (8)
Initial conditions yield p00(0) = 1 − κ, p01(0) = κ and pij(0) = 0 for any other i or j, so that
G(ξ, η, t = 0) = 1− κ+ κη.
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To obtain the HJ equation related to the p.g.f. G(ξ, η, t), we multiply (5) on ξiηj and sum up all
equations for i = 0, 1, . . . , N and j = 0, 1. After some algebra, we obtain
∂G
∂t
=
[
s
(
ξ
∂
∂ξ
+ 1
)− σ(1− η ∂
∂η
)− cη ∂
∂η
+
u(ξ − 1)
2
(
1− ξ
N
∂
∂ξ
)
+
v(η − 1)
2
(
1− η ∂
∂η
)]
G , (9)
where only terms of order greater than or equal to u, v are retained, meaning that terms composed of
the products s, c and u, v are omitted.
Equation (9) is solved by the method of characteristics such that the HJ equation is transformed into
a system of ordinary differential equations (i.e., the system of characteristics, see e.g. [58]).
Constant treatment We study the case for constant σ. Notice that this includes the case of no
treatment (σ = 0).
First, we find the characteristics for the variables ξ and η. Namely, we write using (9):
dξ(t)
dt
= −sξ(t) + uξ(ξ − 1)
2N
,
dη(t)
dt
= (c− σ)η + vη(η − 1)
2
, (10)
which gives
ξ(t) =
s+ u/(2N)
Ae(s+u/(2N))t + u/(2N)
, η(t) =
σ − c+ v/2
Be(σ−c+v/2)t + v/2
, (11)
where A and B are integration constants associated with initial values of ξ(0) and η(0) as
ξ(0) =
s+ u/(2N)
A+ u/(2N)
, η(0) =
σ − c+ v/2
B + v/2
. (12)
The p.g.f. G(ξ, η, t) changes along the characteristic (11)-(12) according to the following ODE
dG(t)
dt
=
(
s− σ + u(ξ(t)− 1)
2
+
v(η(t)− 1)
2
)
G(t) ,
which is straightforward to integrate. Indeed, if we use (10), this yields: d lnG = (s(N + 1) − c)dt +
Nd ln ξ + d ln η. Then, with initial condition G(ξ(0), η(0), 0) = (1− κ) + κη(0), κ is a level of resistance
within a tumor (κ ∈ [0, 1]), (11) and (12), we finally obtain the solution to (9) of the following form
G(ξ, η, t) = G(ξ(0), η(0), 0) exp
[
(s− σ − (u+ v)/2)t+N ln(1 + ξu
2N
e(s+u/(2N))t − 1
s+ u/(2N)
)
+
ln
(
1 +
ηv
2
e(σ−c+v/2)t − 1
σ − c+ v/2
)]
.
Taking into account u, v  s, c and assuming v  σ − c, we can simplify (13) further and write its
approximate form
G(ξ, η, t) ≈
(
1− κ+ κηe
(σ−c)t
1 + ηv2
e(σ−c)t−1
σ−c
)
exp
[
(s− σ)t+N ln(1 + ξu
2N
est − 1
s
)
+ ln
(
1 +
ηv
2
e(σ−c)t − 1
σ − c
)]
,
which can be further simplified and written in the form
G(ξ, η, t) ≈
(
(1− κ)(1 + ηv
2
e(σ−c)t − 1
σ − c ) + κηe
(σ−c)t
)
exp
[
(s− σ)t+N ln(1 + ξu
2N
est − 1
s
)]
. (13)
As expected (13) is linear with respect to η.
The dynamics for the frequency of resistant cells within a tumor (8) is then given by
∂G
∂η
≈
(
(1− κ)v
2
e(σ−c)t − 1
σ − c + κe
(σ−c)t
)
exp
[
(s− σ)t+N ln(1 + ξu
2N
est − 1
s
)]
. (14)
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Figure S1. Tradeoff between growth and resistance under different treatment regimes. (A)
Analytically-derived times for a tumor to reach 109 cells (see equation (1)). (B and C) Sample
distributions for corresponding points B and C, shown in plot A. The bottom panel shows the mean
number of additionally accumulated drivers for all detected tumors over intervals of 3 months. Light
red points indicate tumors with a majority of resistant cells, while light blue points are for tumors
dominated by non-resistant cells. The color-code indicates the level of resistance in detected tumors
over 3 month intervals (see the colorbar on the right for details). Parameters otherwise as in Table 1.
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Figure S2. In the absence of resistance, higher treatment selects for faster growing
subclones. The median (thick blue) and 95% confidence intervals (shaded blue area) for the
distributions of detection times, when a resistant mutation is knocked out. (no initial level of resistance
of a tumor (κ = 0) and zero mutation rate to acquire the resistance v = 0). For comparizon, the case of
non-zero mutation rate v for the same initial conditions is shown besides in orange. The point
color-code indicates the average number of additionally accumulated drivers within detected tumors.
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Figure S3. Sufficiently small tumors can be driven to extinction by low dose therapies.
The median (thick blue) and 95% confidence intervals (shaded area) for the distributions of extinction
times. Red line indicates the probability of extinction, depending on initial cell number. Treatment
level is 0.1%, and no pre-resistance κ = 0.0. Parameters otherwise as in Table 1.
